1206-13-9

Usage

Chemical Properties

clear colourless to yellowish liquid

InChI:InChI=1/C14H17N/c1-12-5-7-13(8-6-12)14(11-15)9-3-2-4-10-14/h5-8H,2-4,9-10H2,1H3

Upstream product

• 2947-61-7 (4-methylphenyl)acetonitrile 
• 111-24-0 1,5-dibromo-pentane 
• 7677-24-9 trimethylsilyl cyanide 
• 1821-23-4 1-cyclohex-1-enyl-4-methylbenzene 

Downstream Products

• 1267707-92-5 1-(p-tolyl)cyclohexanecarbaldehyde 
• 2789-44-8 cyclohexyl(p-tolyl)methanone 
• 84682-27-9 1-p-tolyl-cyclohexanecarboxylic acid 

Relevant academic research and scientific papers

Fe-catalyzed regiodivergent [1,2]-shift of α-aryl aldehydes

An Fe-catalyzed conversion of aldehydes to ketones via [1,2]-shift has been developed. This skeletal rearrangement shows a wide substrate scope and chemoselectivity profile while exhibiting an excellent [1,2]-aryl or [1,2]-alkyl shift selectivity that is easily switched by electronic effects.

Broonsted acid-promoted hydrocyanation of arylalkenes

Nonactivated arylalkenes are effectively converted to tertiary benzylic nitriles in the presence of triflic acid and trimethylsilyl cyanide. The hydrocyanation reactions result in good to excellent yield when electron-donating groups are substituted on the benzene ring. The reaction conditions are mild and relatively safe, notably without need for handling hazardous hydrogen cyanide gas, providing simple and easy access to tertiary benzylic nitriles. The reaction was applied to the preparation of a PDE4 inhibitor (3) as well as a series of analogues.

N-SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS

The present invention relates to N-substituted heterocyclic derivatives of formula: STR1 processes for their preparation, and pharmaceutical compositions which contain them. The compounds according to the invention are non-peptide compounds which oppose the action of angiotensin II. The compounds according to the invention are thus useful in the treatment of cardiovascular disorders such as hypertension and heart failure.

Novel arylcycloalkanepolyalkylamines

Novel arylcycloalkanepolyalkylamines useful as anti-psychotic, anti-ischemia, anti-stroke, anti-dementia and anti-convulsant agents. These arylcycloalkanepolyalkylamines are selective high-affinity ligands to the sigma binding-sites containing three basic units: arylcycloalkyl group, an amine group and an intermediate chain. Their preparation and use for treatment of psychoses, ischemia, stroke, dementia and convulsions are also disclosed.